--- title: "Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Still a Buy?" type: "News" locale: "en" url: "https://longbridge.com/en/news/301607876.md" description: "Inventiva (NASDAQ:IVA) experienced unusually high trading volume, with approximately 872,731 shares traded mid-day. Analyst sentiment remains positive, featuring upgrades from Wall Street Zen and price target increases by Guggenheim and Truist Financial, resulting in a consensus 'Buy' rating and $15.86 target. Institutional investors, including Engineers Gate Manager LP and Eventide Asset Management LLC, have recently increased their holdings. The company reported Q2 EPS of ($0.14) on $0.75 million revenue." datetime: "2026-10-12T16:00:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301607876.md) - [en](https://longbridge.com/en/news/301607876.md) - [zh-HK](https://longbridge.com/zh-HK/news/301607876.md) generator: "portal-rs" --- # Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Still a Buy? Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw unusually-high trading volume on Monday. Approximately 872,731 shares traded hands during mid-day trading, a decline of 2% from the previous session's volume of 893,689 shares. The stock last traded at $3.1750 and had previously closed at $3.16. ## Analyst Upgrades and Downgrades - 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead A number of equities research analysts recently commented on IVA shares. Wall Street Zen upgraded Inventiva from a "sell" rating to a "hold" rating in a research report on Saturday, October 3rd. Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. Guggenheim raised their price target on Inventiva from $11.00 to $14.00 and gave the company a "buy" rating in a report on Tuesday, September 15th. Truist Financial raised their price objective on Inventiva from $13.00 to $18.00 and gave the stock a "buy" rating in a research note on Friday, October 2nd. Finally, Cantor Fitzgerald initiated coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an "overweight" rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $15.86. **Get Our Latest Stock Report on IVA** ## Inventiva Stock Performance The business has a 50-day moving average price of $4.21 and a 200 day moving average price of $4.56. Inventiva (NASDAQ:IVA - Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million during the quarter. As a group, sell-side analysts forecast that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current fiscal year. ## Institutional Trading of Inventiva A number of hedge funds and other institutional investors have recently modified their holdings of the business. Platt Investment Counsel LLC bought a new position in Inventiva in the third quarter worth approximately $45,000. Engineers Gate Manager LP lifted its position in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after buying an additional 43,280 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Inventiva during the fourth quarter valued at $603,000. Seven Fleet Capital Management LP purchased a new position in shares of Inventiva in the 1st quarter worth approximately $1,111,000. Finally, Eventide Asset Management LLC bought a new position in Inventiva during the fourth quarter valued at $1,155,000. 19.06% of the stock is owned by hedge funds and other institutional investors. ## Inventiva Company Profile (Get Free Report) Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. ## See Also - Five stocks we like better than Inventiva - China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit - 3 REITs That May Win in a Higher Interest Rate Environment - Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes - Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Inventiva Right Now? Before you consider Inventiva, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list. While Inventiva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ### Related Stocks - [IVA.US](https://longbridge.com/en/quote/IVA.US.md) ## Related News & Research - [J.P. Morgan Raises Inventiva Voting Rights to 5.21%](https://longbridge.com/en/news/305310429.md) - [IVA: NATiV3 readout could shape lanifibranor’s MASH opportunity and path to a 2028 launch](https://longbridge.com/en/news/304901164.md) - [How New LNG Cruise Ships At Carnival (CCL) Has Changed Its Investment Story](https://longbridge.com/en/news/306370478.md) - [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md) - [Is Bank of America stock a buy at 25% below its 52-week high?](https://longbridge.com/en/news/306369106.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**